Maternal administration of Sildenafil Citrate alters fetal vascular function in a mouse model of fetal growth restriction

Placenta ◽  
2013 ◽  
Vol 34 (9) ◽  
pp. A22
Author(s):  
Lewis Renshall ◽  
Elizabeth Cowley ◽  
Susan Greenwood ◽  
Mark Dilworth ◽  
Mark Wareing
Keyword(s):  
Mouse Model ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Vascular Function ◽  
Growth Restriction ◽  
Sildenafil Citrate ◽  
Maternal Administration

scholarly journals Sildenafil Citrate Increases Fetal Weight in a Mouse Model of Fetal Growth Restriction with a Normal Vascular Phenotype

PLoS ONE ◽  
2013 ◽  
Vol 8 (10) ◽  
pp. e77748 ◽  
Author(s):  
Mark Robert Dilworth ◽  
Irene Andersson ◽  
Lewis James Renshall ◽  
Elizabeth Cowley ◽  
Philip Baker ◽  
...  
Keyword(s):  
Mouse Model ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Growth Restriction ◽  
Fetal Weight ◽  
Sildenafil Citrate ◽  
Vascular Phenotype

scholarly journals Pomegranate Juice Supplementation Alters Utero-Placental Vascular Function and Fetal Growth in the eNOS−/− Mouse Model of Fetal Growth Restriction

2018 ◽  
Vol 9 ◽  
Author(s):  
Sarah L. Finn-Sell ◽  
Elizabeth C. Cottrell ◽  
Susan L. Greenwood ◽  
Mark R. Dilworth ◽  
Elizabeth J. Cowley ◽  
...  
Keyword(s):  
Mouse Model ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Vascular Function ◽  
Growth Restriction ◽  
Pomegranate Juice

Effect of sildenafil citrate treatment in the eNOS knockout mouse model of fetal growth restriction on long-term cardiometabolic outcomes in male offspring

2018 ◽  
Vol 137 ◽  
pp. 122-134 ◽  
Author(s):  
Valerie Mills ◽  
Jasmine F. Plows ◽  
Huan Zhao ◽  
Charlotte Oyston ◽  
Mark H. Vickers ◽  
...  
Keyword(s):  
Mouse Model ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Knockout Mouse ◽  
Growth Restriction ◽  
Male Offspring ◽  
Sildenafil Citrate ◽  
Knockout Mouse Model

scholarly journals The role of sildenafil citrate in the treatment of fetal growth restriction: a randomized controlled trial

2019 ◽  
Vol 8 (5) ◽  
pp. 1840
Author(s):  
Ahmed Abdelshafy ◽  
Khaled Ibrahim Abdullah ◽  
Sherif Ashoush ◽  
Heba E. Hosni
Keyword(s):  
Middle Cerebral Artery ◽  
Fetal Growth ◽  
Cerebral Artery ◽  
Fetal Growth Restriction ◽  
Umbilical Artery ◽  
Controlled Trial ◽  
Maternity Hospital ◽  
Growth Restriction ◽  
Sildenafil Citrate ◽  
Doppler Velocity

Background: This study was aimed to evaluate the effect of sildenafil citrate on Doppler velocity indices in patients with fetal growth restriction (FGR) associated with impaired placental circulation.Methods: A double-blinded, parallel group randomized clinical trial (clinicaltrials.gov NCT02590536) was conducted in Ain Shams Maternity Hospital, in the period between October 2015 and June 2017. Ninety pregnant women with documented intrauterine growth retardation at 24-37 weeks of gestation were randomized to either sildenafil citrate 25 mg orally every 8 hours or placebo visually-identical placebo tablets with the same regimen. The primary outcome of the study was the change in umbilical artery and fetal middle cerebral artery indices.Results: There was a significant improvement in umbilical and middle cerebral artery indices after sildenafil administration p<0.001. Present study observed that, sildenafil group, in comparison to placebo, has a significantly higher mean neonatal birth weight. 1783±241g vs 1570±455g (p<0.001). There was a significantly higher mean gestational age at delivery in women in sildenafil group 35.3±1.67 weeks, whereas it was lower in the placebo group 33.5±1.7 weeks. The side effects as headache, palpitation and facial flushing were significantly higher in sildenafil group compared to placebo group.Conclusions: The use sildenafil citrate in pregnancies with fetal growth restriction (FGR) improved the feto-placental Doppler indices (pulsatility index of umbilical artery and middle cerebral artery) and improved neonatal outcomes.

scholarly journals Cigarette exposure induces changes in maternal vascular function in a pregnant mouse model

2010 ◽  
Vol 298 (5) ◽  
pp. R1249-R1256 ◽  
Author(s):  
Robin E. Gandley ◽  
Arun Jeyabalan ◽  
Ketaki Desai ◽  
Stacy McGonigal ◽  
Jennifer Rohland ◽  
...  
Keyword(s):  
Mouse Model ◽  
Cigarette Smoke ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Smoke Exposure ◽  
Renal Arteries ◽  
Growth Restriction ◽  
Whole Body ◽  
Cigarette Smoke Exposure ◽  
Pregnant Mice

Smoking is associated with multiple adverse pregnancy outcomes, including fetal growth restriction. The objective of this study was to determine whether cigarette smoke exposure during pregnancy in a mouse model affects the functional properties of maternal uterine, mesenteric, and renal arteries as a possible mechanism for growth restriction. C57Bl/CJ mice were exposed to whole body sidestream smoke for 4 h/day. Smoke particle exposure was increased from day 4 of gestation until late pregnancy ( day 16–19), with mean total suspended particle levels of 63 mg/m3, representative of moderate-to-heavy smoking in humans. Uterine, mesenteric, and renal arteries from late-pregnant and virgin mice were isolated and studied in a pressure-arteriograph system ( n = 23). Plasma cotinine was measured by ELISA. Fetal weights were significantly reduced in smoke-exposed compared with control fetuses (0.88 ± 0.1 vs. 1.0 ± 0.08 g, P < 0.02), while litter sizes were not different. Endothelium-mediated relaxation responses to methacholine were significantly impaired in both the uterine and mesenteric vasculature of pregnant mice exposed to cigarette smoke during gestation. This difference was not apparent in isolated renal arteries from pregnant mice exposed to cigarette smoke; however, relaxation was significantly reduced in renal arteries from smoke-exposed virgin mice. In conclusion, we found that passive cigarette smoke exposure is associated with impaired vascular relaxation of uterine and mesenteric arteries in pregnant mice. Functional maternal vascular perturbations during pregnancy, specifically impaired peripheral and uterine vasodilation, may contribute to a mechanism by which smoking results in fetal growth restriction.

scholarly journals Sildenafil citrate: a wonder drug for the management of fetal growth restriction and oligohydramnios

2016 ◽  
Vol Volume 8 ◽  
pp. 367-372 ◽  
Author(s):  
Rana Choudhary ◽  
KAVITA DESAI ◽  
Hetal Parekh ◽  
KEDAR GANLA
Keyword(s):  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Growth Restriction ◽  
Sildenafil Citrate ◽  
Wonder Drug
Sign in / Sign up

Export Citation Format

Share Document